Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), are often associated with the onset of aging. Most of the current biomarker assays for neurodegenerative diseases are based on expensive and invasive techniques, then the search for biomarkers that can be detected by cost-effective, highly comfortable techniques is of great application.
DNA methylation is one of the more widely studied epigenetic biomarkers. There is also a growing research effort to identify and validate DNA methylation changes in aging and age-related neurodegenerative diseases, thus DNA methylation may have great potential as an early diagnostic biomarker for neurodegenerative diseases. CD BioSciences can provide DNA methylation biomarker discovery services for neurodegenerative diseases.
Our DNA Methylation Biomarker Discovery Services for Aging-Related Diseases
Potential biomarker discovery (DNA methylation level analysis and loci identification)
- Candidate gene strategies. Our expertise in candidate gene strategies involves the meticulous selection of target genes based on existing knowledge of their involvement in aging processes and neurodegenerative pathways. By narrowing down the scope to predetermined genetic loci with known biological relevance, we help our clients streamline the biomarker discovery process and delve deeper into the molecular mechanisms underpinning disease etiology.
- Genome-wide strategies. We utilize genome-wide strategies encompassing genomic platforms and computational tools to unravel the complexity of DNA methylation patterns in aging-related neurodegenerative diseases. By integrating multi-omics data, we unearth hidden correlations and uncover novel biomarkers with the potential to revolutionize disease diagnosis and management.
Potential biomarker validation
We employ molecular biology techniques to validate the identified DNA methylation biomarkers. Our services involve confirming the differential methylation status of specific loci across a larger cohort of samples, including neurodegenerative diseases and healthy controls.
Validated biomarker analysis evaluation
We undertake an in-depth evaluation of these biomarkers, examining their sensitivity, specificity, and predictive value with neurodegenerative diseases. Our comprehensive assessment aims to ascertain the clinical significance and diagnostic potential of the identified biomarkers in stratifying disease subtypes, predicting disease progression, or serving as indicators of treatment response.
Applications of DNA Methylation Biomarker Discovery in Aging-Related Neurodegenerative Diseases
- Our services can be applied to combine DNA methylation testing with existing diagnostic tools/biomarkers for aging-related neurodegenerative diseases to aid in the rapid execution of early detection, diagnosis, and therapy formulation.
- Our services can be applied to discern the heterogeneity inherent in aging and neurodegenerative diseases, which enhance the identification of hereditary neurodegenerative diseases.
- Our discovery services of aging-associated differentially methylated positions/regions can be applied to the development of personalized therapies.
Our Advantages
- Advanced technology platforms
We have a comprehensive and proven DNA methylation analysis technology, as well as unique DNA methylation age clocks, and other age clock technologies that combine to form a complete technology platform for aging longevity and other age-related studies.
- Trusted professional teams
Our team has researchers specializing in epigenetics, and related disease areas, which have cutting-edge domain knowledge and extensive research experience. They can select the best DNA methylation biomarker strategy according to the customer's research field and application direction.
CD BioSciences specializes in research and technology supply based on DNA methylation analysis assays, mainly for biotechnology, healthcare, and other industries related to DNA methylation analysis. We are committed to providing customized services to help clients overcome technical difficulties in research and accelerate the discovery and application of DNA methylation biomarkers. If you have any related ideas, please feel free to contact us and we help you to realize your DNA methylation biomarker discovery project.
Reference
- Jakubowski JL and Labrie V. Epigenetic Biomarkers for Parkinson's Disease: From Diagnostics to Therapeutics. Journal of Parkinson's Disease, 2017: 1-12.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
